Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy

We analyzed a cohort of 26 patients with chronic myeloid leukemia who had failed imatinib and a second tyrosine kinase inhibitor but were still in first chronic phase and identified prognostic factors for response and outcomes. The achievement of a prior cytogenetic response on imatinib or on second...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Blood
المؤلفون الرئيسيون: Ibrahim, Amr R., Paliompeis, Christos, Bua, Marco, Milojkovic, Dragana, Szydlo, Richard, Khorashad, Jamshid S., Foroni, Letizia, Reid, Alistair, de Lavallade, Hugues, Rezvani, Katayoun, Dazzi, Francesco, Apperley, Jane F., Goldman, John M., Marin, David
التنسيق: Artigo
اللغة:Inglês
منشور في: American Society of Hematology 2010
الموضوعات:
Clinical Trials and Observations
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC6143154/
https://ncbi.nlm.nih.gov/pubmed/20833982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-06-291922
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة